Search Results
Your search for ASCO ,ASCO matches 20673 pages
Showing 351 - 400PSA May Be Insufficient to Detect Early Prostate Cancer in Transgender Women
Transgender women receiving hormone therapy may skew artificially low on prostate cancer screening tests, thereby providing false reassurance and potentially delaying diagnosis and treatment, according to a recent study published by Nik-Ahd et al in JAMA. The findings indicated that transgender...
Impact of Cisplatin-Based Chemotherapy on Hearing in Cancer Survivors
Researchers have uncovered the long-term effects of cisplatin-based chemotherapy on the hearing of cancer survivors, according to a recent study published by Sanchez et al in JAMA Oncology. Background Cisplatin is commonly used in chemotherapy to treat a variety of cancer types, including...
Tai Chi vs Cognitive Behavioral Therapy: Measuring Inflammatory Biomarkers in Breast Cancer Survivors With Insomnia
Both tai chi and cognitive behavioral therapy may reduce insomnia and inflammation and bolster antiviral defenses in breast cancer survivors, according to a recent study published by Irwin et al in Brain, Behavior, and Immunity. Background Chronic insomnia—one of the most prominent symptoms...
New Study Demonstrates Similar Outcomes Between Patients With Protocol Exceptions to Participate in Targeted Therapy Trial and Eligible Participants
Patients with treatment-refractory tumors who received eligibility and testing waivers to participate in a large basket/umbrella oncology trial demonstrated similar rates of clinical benefit and adverse events compared with patients who participated in the trial without waivers, according to recent ...
In Gastroesophageal Cancer, ‘Switch’ Maintenance Improves Outcomes Over Chemotherapy Continuation
In patients with advanced HER2-negative gastric or gastroesophageal junction cancer and disease control after oxaliplatin-based chemotherapy, “switch” maintenance with paclitaxel plus ramucirumab in the phase III ARMANI trial significantly improved both progression-free and overall survival,...
ASCO: SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery
The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...
ASCO, Friends of Cancer Research Applaud FDA Draft Guidance
The Association for Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) are applauding efforts by the U.S. Food and Drug Administration (FDA) to broaden eligibility criteria for cancer clinical trials in order to include more diverse patient populations. In joint comments submitted on ...
ASCO to Present Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award
ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium. This year’s meeting will be held in San Francisco and online on...
Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...
Strategies for Reducing the Risk of Cancers in Patients With Alcohol Dependence
Investigators have uncovered the potential benefit of undergoing alcohol rehabilitation and maintaining abstinence in patients with alcohol dependence at risk of developing alcohol-associated cancers, according to a recent study published by Schwarzinger et al in The Lancet Public Health. The...
Novel Spatial Gene-Signature Approach May Help to Predict Immunotherapy Outcomes in Patients With Melanoma
Researchers have demonstrated that spatial gene signatures may enhance the prediction of immunotherapy outcomes in patients with melanoma, according to a recent study published by Aung et al in Clinical Cancer Research. The current gene signatures used to predict immunotherapy outcomes may lack...
Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options
Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may...
Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study
Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; ...
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma
On June 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy. EPCORE ...
Can Chemotherapy Impact the Gut Microbiome in Patients With Breast Cancer?
Researchers have uncovered the impact of chemotherapy on the gut microbiome in patients with breast cancer, according to a recent study published by Otto-Dobos et al in Brain, Behavior, and Immunity. Background Chemotherapy is known to cause behavioral side effects, including cognitive decline....
Novel Biomarker May Be Predictive of Clear Cell Renal Cell Carcinoma Recurrence
Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology. Background Approximately 3% to 5% of all cancer diagnoses ...
Phase III postMONARCH Trial: Switching to Abemaciclib May Improve Outcomes After Disease Progression
For hormone receptor–positive, HER2-negative advanced breast cancer that has progressed on CDK4/6 inhibition plus endocrine therapy, the CDK4/6 inhibitor abemaciclib plus fulvestrant significantly reduced the risk of further disease progression in the phase III postMONARCH study.1 “The postMONARCH ...
New Survey Finds Cancer Drug Shortage Management Remains a Moving Target
The National Comprehensive Cancer Network® (NCCN®) published new results from its latest survey on cancer drug shortages in the United States. This follows data published 1 year ago and 6 months ago illustrating how up to 93% of centers surveyed were experiencing shortages of the crucial...
Can Acupuncture Improve Hormonal Side Effects in Women Undergoing Breast Cancer Therapy?
Acupuncture may be effective at reducing the hormonal side effects of endocrine therapy in women with breast cancer, according to a recent study published by Lu et al in Cancer. Background Although endocrine therapy—which is capable of blocking the hormone signaling that drive some types of...
Early Surveillance in Pediatric Patients Genetically Predisposed to Cancer
Initiating surveillance soon after recognizing a pediatric patient has a genetic predisposition for cancer may improve the identification of early-stage asymptomatic tumors, according to a recent study published by Blake et al in JAMA Oncology. The findings may inform clinical practice following...
Estrogen Alone Increased Ovarian Cancer Incidence and Mortality, Combination Hormone Therapy Did Not
In 2002, the federally funded Women’s Health Initiative (WHI),1 a randomized, placebo-controlled clinical trial investigating menopausal hormone therapy for healthy menopausal women, was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause increased the ...
ASCO Sets Six Guiding Principles for AI in Oncology
ASCO has released “Principles for the Responsible Use of Artificial Intelligence in Oncology,” to guide the Society’s consideration of all aspects of artificial intelligence (AI). With this manuscript, ASCO joins colleagues across medicine in offering principles that should be applied in...
ASCO Issues New Guidance on Cannabis and Cannabinoid Use in Adults With Cancer
Many Americans, including patients with cancer, use cannabis and cannabinoids. In response to this reality, ASCO has issued a guideline for clinicians, adults with cancer, caregivers, and researchers on their medical use.1 The recommendations cover all cancer types and address products ranging from ...
Long-Term Study Finds Most Breast Cancer Survivors Were Able to Preserve Fertility and Achieve Pregnancy After Diagnosis
Research examining fertility and attempts at pregnancy among young women after a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. However, a long-term study investigating fertility outcomes among young women who reported...
Retroperitoneal Lymphadenectomy: Can It Be Safely Omitted for Some Patients With Advanced Ovarian Cancer?
Adding retroperitoneal lymphadenectomy to cytoreductive surgery during primary debulking surgery or interval cytoreductive surgery after neoadjuvant chemotherapy failed to improve progression-free or overall survival in patients with advanced ovarian cancer who have no suspicious nodes, according...
DREAMM-8: Belantamab Mafodotin-blmf Shows ‘Robust’ Benefit in Early Relapse of Myeloma
Recent phase III findings support the antibody-drug conjugate belantamab mafodotin-blmf as a treatment option for patients with multiple myeloma in early relapse. Belantamab mafodotin is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) expressed on multiple myeloma cells,...
Advanced Lung Cancer: Studies Explore Palliative Care Delivered by Telehealth and in a Stepped-Care Approach
Early palliative care can be integrated into the course of treatment for patients with advanced lung cancer via delivery by telehealth with outcomes similar to when palliative care is delivered via in-person visits, according to results of the REACH PC trial presented by Joseph Greer, PhD, of...
Accelerating Progress in Melanoma and Cancer Research
The Melanoma Research Alliance is on a mission to cure and prevent melanoma, a skin cancer that is diagnosed in more than 100,000 people each year and is expected to take the lives of more than 8,000 individuals in 2024.1 We invite stakeholders across all fields, including medicine, science, and...
Durvalumab Consolidation Therapy Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradiotherapy alone, according to the first planned interim analysis of the phase III ADRIATIC trial...
CSHL and Northwell Health Extend Strategic Affiliation
Leaders from two New York bioscience and health-care institutions came together at Carnegie Hall to acknowledge the signing of an update to their affiliation agreement initiated in 2015. The Cold Spring Harbor Laboratory (CSHL)-Northwell Health agreement ensures continued collaboration and support...
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma
As reported at the 2024 ASCO Annual Meeting (Abstract 9500) and in The New England Journal of Medicine by Georgina V. Long, MD, PhD, and colleagues, the final, 8-year follow-up analysis of the phase III COMBI-AD trial has shown continued improvements in relapse-free and distant metastasis–free...
ASTRO Names New Chief Executive Officer
The American Society for Radiation Oncology (ASTRO) announced that following a nationwide search, Vivek S. Kavadi, MD, MBA, FASTRO, will become Chief Executive Officer of the Society, effective November 1, 2024. Dr. Kavadi will succeed Laura Thevenot, who had already announced her intent to retire...
Immunoglobulin G Testing May Reduce Infections, Increase Receipt of Immunoglobulin Replacement Therapy in Patients With CLL and NHL
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) who undergo frequent immunoglobulin G testing may be less likely to experience severe infections than those who don’t undergo frequent testing, according to a recent study published by Soumerai et al in Blood Advances....
Modified Perioperative Chemotherapy Regimen May Benefit Patients With Pancreatic Ductal Adenocarcinoma
Administering chemotherapy prior to and following surgery may extend survival in patients with pancreatic ductal adenocarcinoma compared with postoperative administration alone, according to a recent study published by Cecchini et al in JAMA Oncology. The findings may be encouraging for the 15% to...
FDA Grants Accelerated Approval to Adagrasib With Cetuximab for KRAS G12C–Mutated Colorectal Cancer
On June 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the KRAS G12C inhibitor adagrasib (Krazati) plus cetuximab for adults with KRAS G12C–mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior...
Air Pollution May Increase Cardiovascular Risk in Patients With Cancer
Air pollution may increase the risk of cardiovascular disease, mortality, and health disparities in patients with cancer, according to a recent study published by Zhu et al in JACC: CardioOncology. Background Although modern therapies may help extend the lives of patients with cancer, cancer...
Repurposing Brigatinib to Treat NF2-Related Schwannomatosis
Researchers have found that brigatinib may be effective in treating patients with NF2-related schwannomatosis, according to a recent study published by Plotkin et al in The New England Journal of Medicine. The findings revealed a potential new treatment option for the genetic syndrome. Background...
Clinical Trial Testing Brenetafusp Plus Nivolumab in Advanced or Metastatic Cutaneous Melanoma Kicks Off
On June 18, the first patient was randomized into the PRISM-MEL-301 trial (ClinicalTrials.gov identifier NCT06112314), which is assessing the efficacy and safety of brenetafusp (also known as IMC-F106C; PRAME-A02) in combination with nivolumab in the first-line setting of advanced or metastatic...
Celecoxib May Benefit a Subset of Patients With PIK3CA Mutations
Researchers have found that administering the anti-inflammatory drug celecoxib after surgery may improve disease-free survival in a subset of patients with PIK3CA-mutated stage III colorectal cancer, according to a study published by Nowak et al in the Journal of Clinical Oncology. The findings...
Updated ASTRO Clinical Guidelines on Radiation Therapy for HPV-Positive Oropharyngeal Cancer
The American Society for Radiation Oncology (ASTRO) detailed best practices for using radiation therapy as a stand-alone curative treatment or in combination with surgery and/or chemotherapy to treat patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma,...
Do Patients With Cancer Require Additional COVID-19 Vaccine Doses?
Findings from a Spanish study on the effectiveness of vaccines against COVID-19 infection among patients with cancer recommend administering additional doses of the vaccine to this at-risk population. These data were published by Neto et al in Nature Communications. Patients with cancer are at an...
Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center
Robert L. Ferris, MD, PhD, a head and neck surgical oncologist, has been named the Executive Director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center and UNC System Chief of Oncology Services, effective October 1, announced the Dean of the UNC School of Medicine...
Study Evaluates Cancer Screening Behaviors Among a Population of Muslim Individuals
Investigators uncovered crucial insights into the cancer screening behaviors of a population of Muslim individuals residing in the Washington, DC, metropolitan area that could help illuminate the influence of cultural and religious beliefs on health practices, according to a recent study published...
Machine-Learning Model May Aid in Early Diagnosis of Hepatocellular Carcinoma
A serum fusion-gene machine-learning model may offer early diagnostic accuracy and could help improve the 5-year survival rate in patients with hepatocellular carcinoma, according to a recent study published by Yu et al in The American Journal of Pathology. Background Hepatocellular carcinoma is...
Phase I Study in NHL: Use of ‘Armored’ CAR T Cells May Be Feasible After Standard CAR T-Cell Failure
A novel “armored” chimeric antigen receptor (CAR) T cell appears to be feasible for retreatment of patients with non-Hodgkin lymphoma (NHL) who fail to respond to standard CAR T-cell therapy, according to preliminary results of a phase I trial presented at the 2024 ASCO Annual Meeting.1 The unique...
Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer
Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...
Can FAP-Targeted Radioligand Therapy Benefit Patients With Advanced Sarcomas?
Fibroblast activation protein (FAP)-targeted radioligand therapy may be safe and effective in patients with progressive metastatic tumors, particularly advanced sarcomas, according to new findings presented by Lanzafame et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI)...
FAPI PET/CT May Improve Staging in Newly Diagnosed Breast Cancer
Researchers have found that fibroblast activation protein inhibitor (FAPI) positron-emission tomography/computed tomography (PET/CT) may offer more accurate staging in patients with newly diagnosed breast cancer than fluorine (F)-18–labeled fluorodeoxyglucose (FDG) PET/CT, according to new findings ...
FDA Approves Blinatumomab as Consolidation for CD19-Positive, Ph-Negative B-Cell Precursor ALL
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto) for adult and pediatric patients aged 1 month and older with CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of...
FDA Approves Two Immunochemotherapy Combinations for Endometrial Cancer
On June 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel followed by single-agent pembrolizumab for adult patients with primary advanced or recurrent endometrial carcinoma; on June 14, the agency approved durvalumab...
